Amyloidosis is a group of rare but very serious, usually fatal diseases caused by the aggregation of body’s own proteins to form amyloid deposits in vital organs. Immutrin is a Cambridge-based biotech company that is developing the next generation antibody therapies for systemic and local amyloidosis.
Company Details
- Employees
- 6
- Address
- Cambridge, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Cambridge
Immutrin Questions
Immutrin's LinkedIn profile is https://uk.linkedin.com/company/immutrin
Immutrin has
6 employees.
View email and phone details for 6
employees at Immutrin.
Immutrin's industry is
Biotechnology Research
Immutrin's top competitors are
Healthspan Biotics,
Awen Oncology,
Myimmune,
Avatrial,
Epitopea,
Outsee,
Trimtech Therapeutics Limited,
Cambridge Innovation Capital,
Clock.bio,
T-Therapeutics Ltd.
Immutrin's categories are Biotechnology Research
